Literature DB >> 35101168

WHO Recommendation Should Be Critically Discussed.

Mathias Sonnhoff, Mandy Graff.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 35101168      PMCID： PMC8830349          DOI： 10.3238/arztebl.m2021.0285

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   8.251


× No keyword cloud information.
  4 in total

1.  Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.

Authors:  Michael T Milano; Alan W Katz; Hong Zhang; Christine F Huggins; Khush S Aujla; Paul Okunieff
Journal:  Radiother Oncol       Date:  2018-12-28       Impact factor: 6.280

Review 2.  Symptoms During Outpatient Cancer Treatment and Options for Their Management

Authors:  Mitra Tewes; Freerk Baumann; Martin Teufel; Christoph Ostgathe
Journal:  Dtsch Arztebl Int       Date:  2021-04-30       Impact factor: 5.594

3.  A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.

Authors:  Amit Maity; Rosemarie Mick; Alexander C Huang; Sangeeth M George; Michael D Farwell; John N Lukens; Abigail T Berman; Tara C Mitchell; Josh Bauml; Lynn M Schuchter; Mark O'Hara; Lilie L Lin; Angela Demichele; John P Christodouleas; Naomi B Haas; Dana M Patsch; Stephen M Hahn; Andy J Minn; E John Wherry; Robert H Vonderheide
Journal:  Br J Cancer       Date:  2018-10-15       Impact factor: 7.640

4.  Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre.

Authors:  Cedric Peters; Julie Vandewiele; Yolande Lievens; Marc van Eijkeren; Valérie Fonteyne; Tom Boterberg; Pieter Deseyne; Liv Veldeman; Wilfried De Neve; Chris Monten; Sabine Braems; Fréderic Duprez; Katrien Vandecasteele; Piet Ost
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.